drugset / Trial / NCT06182969
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
Phase 1/2
Recruiting
40 enrolled
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).
Timeline
- Start
- 2024-08-09
- Primary completion
- 2026-04
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-2575 | Small molecule | 200 mg | Oral |
| Subject | APG-2575 | Small molecule | 800 mg | Oral |